<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409511</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISED Substudy</org_study_id>
    <nct_id>NCT02409511</nct_id>
  </id_info>
  <brief_title>Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)</brief_title>
  <official_title>Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microalbuminuria (MA) is an independent cardiovascular risk factor in diabetic and
      non-diabetic subjects.

      However, in the setting of type 2 diabetes, microalbuminuria could be a marker of either
      early diabetic nephropathy or diffuse endothelial dysfunction. At present, there are no
      biomarkers that permit us to discriminate between these two conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A hypothesis free approach by using proteomic/metabolomic analyses in the urine samples of
      selected populations seems an appropriate approach by which to explore this issue. In
      addition, a driven hypothesis in the same groups of patients based on a sensitive marker of
      kidney injury also seems appropriate.

      Urinary levels of KIM-1(Kidney Injury Molecule-1 ) have been found elevated in experimental
      diabetic nephropathy even before that MA . In addition, urinary levels of KIM-1 were found
      significantly elevated in type 1 diabetic patients with MA, in comparison with diabetics with
      normoalbuminuria and non-diabetic healthy controls. Moreover, low urinary KIM-1 levels at
      baseline were associated with the regression of MA during a follow-up of 2 years . Therefore,
      it could be hypothesized that the presence of MA + KIM-1 in urine samples would indicate
      renal injury rather than endothelial dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To find markers for a better definition of the meaning of microalbuminuria</measure>
    <time_frame>3 years</time_frame>
    <description>Improve diagnosis of diabetic nephropathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complementary markers for improving the performance of MA</measure>
    <time_frame>3 years</time_frame>
    <description>Improve diagnosis of diabetic nephropathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify candidates which could help to discriminate whether microalbuminuria is related to endothelial dysfunction rather than kidney damage</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test whether the enhancement of this specific marker of kidney injury is able to identify those patients in which MA really means diabetic nephropathy.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Microalbuminuria</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetic, retinopathy, non cardiovascular disease</arm_group_label>
    <description>Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic, hipertension</arm_group_label>
    <description>Non-diabetic patients with hypertension and microalbuminuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic, non diabetic retinopathy</arm_group_label>
    <description>Type 2 diabetic patients without diabetic retinopathy and microalbuminuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic with diabetic retinopathy</arm_group_label>
    <description>Type 2 diabetic patients with diabetic retinopathy and microalbuminuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetic, with proven nephropathy</arm_group_label>
    <description>Type 2 diabetic patients with biopsy proven diabetic nephropathy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non intervention</intervention_name>
    <arm_group_label>Type 1 diabetic, retinopathy, non cardiovascular disease</arm_group_label>
    <arm_group_label>Non-diabetic, hipertension</arm_group_label>
    <arm_group_label>Type 2 diabetic, non diabetic retinopathy</arm_group_label>
    <arm_group_label>Type 2 diabetic with diabetic retinopathy</arm_group_label>
    <arm_group_label>Type 2 diabetic, with proven nephropathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with diabetes mellitus type 2 with microalbuminuria with and without
        retinopathy.

        Control groups: diabetes mellitus type 1 with microalbuminuria and retinopathy hypertensive
        patients with microalbuminuria and diabetic patients with a renal biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with diabetes mellitus type 2 with microalbuminuria with and without
             retinopathy.

        Control groups: diabetes mellitus type 1 with microalbuminuria and retinopathy hypertensive
        patients with microalbuminuria and diabetic patients with a renal biopsy

        Exclusion Criteria:

          -  Patients without microalbuminuria or patients with macroalbuminuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Garcia-Dorado Garcia, PhD MD</last_name>
    <phone>34 93 489 40 38</phone>
    <email>dgdorado@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Garcia-Dorado Garcia, PhD MD</last_name>
      <phone>34 93 489 4038</phone>
      <email>dgdorado@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Joan Montaner Vilallonga, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rafael Simo Canonge, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Sayos Ortega, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Serón Micas, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Genesca Ferrer, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Aguadé Bruix, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Xavier Comella Carnicé, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002 Jul;62(1):237-44.</citation>
    <PMID>12081583</PMID>
  </reference>
  <reference>
    <citation>Huo W, Zhang K, Nie Z, Li Q, Jin F. Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury. Transplant Rev (Orlando). 2010 Jul;24(3):143-6. doi: 10.1016/j.trre.2010.02.002. Epub 2010 May 6. Review.</citation>
    <PMID>20447817</PMID>
  </reference>
  <reference>
    <citation>Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, Stasch JP, Hocher B. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab. 2012;58(7-8):659-71.</citation>
    <PMID>22997966</PMID>
  </reference>
  <reference>
    <citation>Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int. 2011 Feb;79(4):464-70. doi: 10.1038/ki.2010.404. Epub 2010 Oct 27.</citation>
    <PMID>20980978</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetic</keyword>
  <keyword>Type 2 Diabetic</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Renal Injury</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

